3D Medicines Inc. (01244.HK): Positive Data from Global Pivotal Phase III REGAL Trial of 3D189
1 day ago / Read about 0 minute
Author:小编   

3D Medicines Inc. and SELLAS have announced topline results from the global pivotal randomized Phase III REGAL trial of their jointly developed pipeline product, 3D189. The trial evaluated 3D189 as monotherapy maintenance treatment in patients with acute myeloid leukemia (AML) who had achieved second or later complete remission following treatment and were unable to undergo allogeneic stem cell transplantation. The trial successfully met its prespecified primary efficacy endpoint: compared with the best available treatment, 3D189 reduced the risk of death by 41% (hazard ratio 0.59, two-sided p-value 0.035), demonstrating both statistical significance and clinical meaningfulness. Median overall survival in the 3D189 arm reached 24.0 months, significantly superior to 14.7 months in the control arm. The product was generally well tolerated, with no new safety signals observed; treatment-related adverse events were mostly mild-to-moderate local injection reactions. SELLAS plans to engage with the FDA regarding an accelerated approval pathway and intends to submit a Biologics License Application in the first half of 2027. Complete trial data will be presented at future international medical conferences and published in academic journals.